Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)

Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study

(2012) Yi-Long Wu et al.   LUNG CANCER

Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer

(2011) A G Pallis et al.   BRITISH JOURNAL OF CANCER

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

(2011) Yosuke Togashi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Medical Management of Patients With Brain Tumors

(2011) Amy A. Pruitt   Current Treatment Options in Neurology

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor

(2011) Britta Weber et al.   Journal of Thoracic Oncology

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy

(2011) Seung Tae Kim et al.   LUNG CANCER

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

(2011) C. Grommes et al.   NEURO-ONCOLOGY

Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients

(2011) Ameer L Elaimy et al.   World Journal of Surgical Oncology

Treatment of Brain Metastases: Chemotherapy

(2011) Sean A. Grimm   Current Oncology Reports

Multimodality management of non-small cell lung cancer patients with brain metastases

(2010) Serena Ricciardi et al.   CURRENT OPINION IN ONCOLOGY

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

(2010) R. Porta et al.   EUROPEAN RESPIRATORY JOURNAL

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

(2010) Jennifer L. Clarke et al.   JOURNAL OF NEURO-ONCOLOGY

Risk of Intracranial Hemorrhage and Cerebrovascular Accidents in Non-small Cell Lung Cancer Brain Metastasis Patients

(2010) Geetika Srivastava et al.   Journal of Thoracic Oncology

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI

(2008) Hyeon Gyu Yi et al.   LUNG CANCER